Patents by Inventor Edward T. Olejniczak

Edward T. Olejniczak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF
    Publication number: 20160106731
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Inventors: Taekyu Lee, Jason P. Burke, Edward T. Olejniczak, Johannes Belmar, Zhiguo Bian, Stephen W. Fesik
  • SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS
    Publication number: 20150336925
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: September 20, 2013
    Publication date: November 26, 2015
    Applicant: VANDERBILT UNIVERSITY
    Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
  • Antibodies that bind to mammalian NGAL and uses thereof
    Patent number: 8846036
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 30, 2014
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Robert N. Ziemann, Frank C. Grenier, Ryan F. Workman, Lowell Tyner
  • Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
    Patent number: 8263558
    Abstract: The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: September 11, 2012
    Assignees: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Thomas F. Holzman, John E. Harlan, Rohinton P. Edalji, Edward T. Olejniczak, Ana Pereda-Lopez, Boris Labkovsky, Liping Yu, Heinz Hillen, Stefan Barghorn, Ulrich M. Ebert
  • IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL
    Publication number: 20100227775
    Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.
    Type: Application
    Filed: May 21, 2010
    Publication date: September 9, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Ryan F. Workman, Robert N. Ziemann
  • IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL
    Publication number: 20090269777
    Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.
    Type: Application
    Filed: April 16, 2008
    Publication date: October 29, 2009
    Applicant: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, Ryan F. Workman, Robert N. Ziemann
  • ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF
    Publication number: 20090263894
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Application
    Filed: December 5, 2008
    Publication date: October 22, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
  • METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS
    Publication number: 20090214515
    Abstract: The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.
    Type: Application
    Filed: November 30, 2006
    Publication date: August 27, 2009
    Inventors: Thomas F. Holzman, John E. Harlan, Rohinton P. Edalji, Edward T. Olejniczak, Ana Pereda-Lopez, Boris Labkovsky, Liping Yu, Heinz Hillen, Stefan Barghorn, Ulrich M. Ebert
  • ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF
    Publication number: 20090124022
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Application
    Filed: April 16, 2008
    Publication date: May 14, 2009
    Applicant: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann, Lowell J. Tyner
  • IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL
    Publication number: 20090123946
    Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.
    Type: Application
    Filed: December 5, 2008
    Publication date: May 14, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Ryan F. Workman, Robert N. Ziemann, Lowell J. Tyner
  • Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
    Patent number: 6043024
    Abstract: The present invention provides a process for identifying compounds which bind to a specific target molecule. The process comprises the steps of: a) generating a first T.sub.2 - or diffusion-filtered proton spectrum of one or a mixture of chemical compounds; b) exposing one or a mixture of chemical compounds to the target molecule; c) generating a second T.sub.2 - or diffusion-filtered proton spectrum of one or a mixture of chemical compounds that has been exposed the target molecule in step (b); and d) comparing said first and second T.sub.2 - or diffusion-filtered proton spectra to determine differences between said first and said second spectra, the differences identifying the presence of one or more compounds that are ligands which have bound to the target molecule.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: March 28, 2000
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
  • Use of nuclear magnetic resonance to design ligands to target biomolecules
    Patent number: 5989827
    Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: November 23, 1999
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
  • Use of nuclear magnetic resonance to design ligands to target biomolecules
    Patent number: 5891643
    Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: April 6, 1999
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak